Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults

NCT03739866 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

53

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV-1 Infection

Interventions

DRUG: Lenacapavir
DRUG: Placebo
DRUG: B/F/TAF
DRUG: TAF

Sponsor

Gilead Sciences